[89Zr]-免疫PET预测利妥昔单抗治疗难治性间质性肺炎的疗效:一项2期试验
这项前瞻性2期试验纳入21例常规治疗失败后肺功能恶化的免疫介导间质性肺病患者,给予利妥昔单抗1000 mg(第1天和第14天)并示踪标记[89Zr]-利妥昔单抗,第3天和第6天行PET/CT。15例(71%)为应答者,应答者肺部[89Zr]-利妥昔单抗SUVmean显著高于非应答者(0.35±0.09 vs 0.23±0.06,P=0.02),靶本比与FVC和DLCO变化相关(K=0.49和0.56)。作者认为[89Zr]-利妥昔单抗PET可能作为抗CD20治疗的潜在预测生物标志物。
要点
- 21例难治性免疫介导间质性肺病患者中15例(71%)对利妥昔单抗治疗有应答。
- 应答者肺部[89Zr]-利妥昔单抗SUVmean为0.35(SD 0.09),高于非应答者的0.23(SD 0.06),P=0.02。
- 靶本比与FVC和DLCO变化相关(K=0.49和0.56),但SUVmean单独与变化不相关。
核心结论
- 利妥昔单抗治疗对多数患者有效。
- 肺部[89Zr]-利妥昔单抗摄取较高与肺功能检查改善及治疗结局相关,[89Zr]-利妥昔单抗PET成像可能作为抗CD20治疗的潜在预测生物标志物。
研究设计与样本
- 前瞻性2期试验,纳入21例常规治疗失败后肺功能恶化的免疫介导间质性肺病患者。
- 患者第1天和第14天接受利妥昔单抗1000 mg,并加入示踪剂量的放射性标记[89Zr]-利妥昔单抗,第3天和第6天行PET/CT。
- 以标准化摄取值(SUV)作为肺部CD20表达的测量指标。
- 根据治疗前和治疗后6个月的肺功能检查(PFT)、用力肺活量(FVC)和一氧化碳弥散量(DLCO),将患者分为应答者(疾病稳定或改善)和非应答者。
- 试验注册号:Clinicaltrials.gov NCT02251964。
主要发现
- 15例患者(71%)被归类为应答者。
- 使用靶本比时,肺部[89Zr]-利妥昔单抗PET SUVmean与FVC和DLCO变化显著相关(K=0.49和0.56),但单独使用SUVmean时不相关。
- [89Zr]-利妥昔单抗SUVmean在应答者中显著高于非应答者(0.35 SD 0.09 vs 0.23 SD 0.06;P=0.02)。
关键数值与推荐
- 应答定义为治疗前至治疗后6个月FVC和DLCO稳定或改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immune-mediated interstitial pneumonitis may be treated with anti-CD20 therapy after failure of conventional therapies. However, clinical response is variable. It was hypothesized that autoreactive CD20-positive cells may play an important role in this variability. This prospective study aims to elucidate if imaging of CD20-positive cells in the lungs allows prediction of the response to anti-CD20 treatment. METHODS: Twenty-one patients with immune-mediated interstitial lung disease (ILD) with deteriorated pulmonary function received a dose of 1000 mg rituximab on day 1 and day 14 spiked with a tracer dose of radiolabeled [89Zr]-rituximab. PET/CT was performed on days 3 and 6. Standardized uptake values (SUV) were calculated as a measure for pulmonary CD20 expression. Based on pulmonary function tests (PFT), forced vital capacity (FVC), and diffusing capacity for carbon monoxide (DLCO), prior to and 6 months after treatment, patients were classified as responder (stable disease or improvement) or non-responder. RESULTS: Fifteen patients (71%) were classified as responder. Pulmonary [89Zr]-rituximab PET SUVmean was significantly correlated with the change in FVC and DLCO (K = 0.49 and 0.56, respectively) when using target-to-background ratios, but not when using SUVmean alone. [89Zr]-rituximab SUVmean was significantly higher in responders than in non-responders (0.35 SD 0.09 vs. 0.23 SD 0.06; P = 0.02). CONCLUSION: Rituximab treatment was effective in the majority of patients. As a higher pulmonary uptake of [89Zr]-rituximab correlated with improvement of PFT and treatment outcome, [89Zr]-rituximab PET imaging may serve as a potential predictive biomarker for anti-CD20 therapy. TRIAL REGISTRATION: Clinicaltrials.gov identifier NCT02251964.
引用
- Adams H, van de Garde EMW, Vugts DJ, et al. [89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial. Eur J Nucl Med Mol Imaging. 2023. PMID: 36826476. doi:10.1007/s00259-023-06143-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。